Tigris Pharmaceuticals has enrolled its first patient in a randomized phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with or without Faslodex (fulvestrant) in estrogen receptor (ER)-positive breast cancer patients. Molecular profiling will be used to pre-screen patients for a biomarker called Aryl Hydrocarbon Receptor (AhR), which has shown to predict sensitivity to AFP-464.

It is estimated that approximately 70% of breast cancers are ER-positive. The primary endpoint of the study is to determine the percentage of patients that achieve a Clinical Benefit Response.

"The promise of personalized medicine is being realized with this study of AFP-464," said Edmundo Muniz, M.D., Ph.D., president and chief executive officer of Tigris Pharmaceuticals. "Matching specific markers and gene variations to particular medicines is a more efficient way of developing new anti-cancer agents and more importantly, will enable doctors to make more informed prescribing decisions, reducing risks of side effects and increasing chances of treatment success."